astrazeneca oral glp 1 AstraZeneca's GLP-1 scored phase 2 wins, but no data yet Oral Small-Molecule GLP-1 Receptor Agonists:

Interestingly, a large meta-analysis that included data from 34,043 individuals with NAFLD, who were diagnosed either with imaging studies or histological evidence and were followed over a median period of 6.9 years, suggested that there was a 64% higher risk for experiencing both fatal and nonfatal cardiovascular events vs

Lv et al., 2014

Regarding the hypothesis that oxidative activation of curcumin mediates GLP-1 secretion, there was not a clear-cut distinction between unstable analogues being active and stable ones being inactive

That's by design - the goal is to pick up the conversation right where the ad left off, not throw you into something that reads like a completely different document